These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Prospects for development of new antituberculous drugs]. Tomioka H Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850 [TBL] [Abstract][Full Text] [Related]
4. In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages. Rastogi N; Labrousse V; Goh KS Curr Microbiol; 1996 Sep; 33(3):167-75. PubMed ID: 8672093 [TBL] [Abstract][Full Text] [Related]
5. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations. API Consensus Expert Committee J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350 [TBL] [Abstract][Full Text] [Related]
6. Susceptibility to levofloxacin of Myocobacterium tuberculosis isolates from patients with HIV-related tuberculosis and characterization of a strain with levofloxacin monoresistance. Community Programs for Clinical Research on AIDS 019 and the AIDS Clinical Trials Group 222 Protocol Team. Perlman DC; El Sadr WM; Heifets LB; Nelson ET; Matts JP; Chirgwin K; Salomon N; Telzak EE; Klein O; Kreiswirth BN; Musser JM; Hafner R AIDS; 1997 Oct; 11(12):1473-8. PubMed ID: 9342069 [TBL] [Abstract][Full Text] [Related]
7. Fluoroquinolones for the treatment of pulmonary tuberculosis. Moadebi S; Harder CK; Fitzgerald MJ; Elwood KR; Marra F Drugs; 2007; 67(14):2077-99. PubMed ID: 17883288 [TBL] [Abstract][Full Text] [Related]
8. Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project. Zignol M; Dean AS; Alikhanova N; Andres S; Cabibbe AM; Cirillo DM; Dadu A; Dreyer A; Driesen M; Gilpin C; Hasan R; Hasan Z; Hoffner S; Husain A; Hussain A; Ismail N; Kamal M; Mansjö M; Mvusi L; Niemann S; Omar SV; Qadeer E; Rigouts L; Ruesch-Gerdes S; Schito M; Seyfaddinova M; Skrahina A; Tahseen S; Wells WA; Mukadi YD; Kimerling M; Floyd K; Weyer K; Raviglione MC Lancet Infect Dis; 2016 Oct; 16(10):1185-1192. PubMed ID: 27397590 [TBL] [Abstract][Full Text] [Related]
10. Clinically significant interactions with drugs used in the treatment of tuberculosis. Yew WW Drug Saf; 2002; 25(2):111-33. PubMed ID: 11888353 [TBL] [Abstract][Full Text] [Related]
11. Infection caused by Mycobacterium tuberculosis. Peloquin CA; Berning SE Ann Pharmacother; 1994 Jan; 28(1):72-84. PubMed ID: 8123968 [TBL] [Abstract][Full Text] [Related]
12. Fluoroquinolones for the treatment of tuberculosis in children. Thee S; Garcia-Prats AJ; Donald PR; Hesseling AC; Schaaf HS Tuberculosis (Edinb); 2015 May; 95(3):229-45. PubMed ID: 25797610 [TBL] [Abstract][Full Text] [Related]
14. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
15. Clinical use of Levofloxacin in the long-term treatment of drug resistant tuberculosis. Richeldi L; Covi M; Ferrara G; Franco F; Vailati P; Meschiari E; Fabbri LM; Velluti G Monaldi Arch Chest Dis; 2002 Feb; 57(1):39-43. PubMed ID: 12174702 [TBL] [Abstract][Full Text] [Related]
16. Emergence during unsuccessful chemotherapy of multiple drug resistance in a strain of Mycobacterium tuberculosis. Rastogi N; Ross BC; Dwyer B; Goh KS; Clavel-Sérès S; Jeantils V; Cruaud P Eur J Clin Microbiol Infect Dis; 1992 Oct; 11(10):901-7. PubMed ID: 1362540 [TBL] [Abstract][Full Text] [Related]